Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus (DM), a group of diseases characterized by defective glucose metabolism, is the most widespread metabolic disorder affecting over 400 million adults worldwide. This pathological condition has been implicated in the pathogenesis of a number of central encephalopathies and peripheral neuropathies. In further support of this notion, recent epidemiological evidence suggests a link between DM and Parkinson's disease (PD), with hyperglycemia emerging as one of the culprits in neurodegeneration involving the nigrostriatal pathway, the neuroanatomical substrate of the motor symptoms affecting parkinsonian patients. Indeed, dopaminergic neurons located in the mesencephalic substantia nigra appear to be particularly vulnerable to oxidative stress and degeneration, likely because of their intrinsic susceptibility to mitochondrial dysfunction, which may represent a direct consequence of hyperglycemia and hyperglycemia-induced oxidative stress. Other pathological pathways induced by increased intracellular glucose levels, including the polyol and the hexosamine pathway as well as the formation of advanced glycation end-products, may all play a pivotal role in mediating the detrimental effects of hyperglycemia on nigral dopaminergic neurons. In this review article, we will examine the epidemiological as well as the molecular and cellular clues supporting the potential susceptibility of nigrostriatal dopaminergic neurons to hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931 · cited 1×
“Most importantly, however, glyoxalase employs glutathione to deactivate the AGEs precursor methylglyoxal, while we know that aldose reductase depletes pools of NADPH (Thornalley, 1988; Schieber and Chandel, 2014).”
BackgroundOxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“As described for the induction of oxidative stress, the activation of the RAGE by AGEs triggers deleterious inflammatory pathways (Singh et al., 2001; Jakus and Rietbrock, 2004).”
BackgroundRubinsztein, D. C., Mariño, G., & Kroemer, G. (2011) · Cell · doi:10.1016/j.cell.2011.07.030 · Cited by 2,107 · cited 1×
“, 2014), and malfunction of the ubiquitin-proteasome system and autophagy clearance pathways (Li and Li, 2011; Rubinsztein et al., 2011; Jana, 2012) were all shown to increase drastically with age, especially so in the substantia nigra pars compacta (Dexter et al.”
BackgroundNon-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 1×
“Nonetheless, we cannot overlook the fact that insulin resistance is the main feature of type II DM and that insulin resistance also occurs in the brain (Athauda and Foltynie, 2016a) with defective insulin signaling being identified as an important player in the pathogenesis of neurodegenerative disorders and particula…”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Nonetheless, we cannot overlook the fact that insulin resistance is the main feature of type II DM and that insulin resistance also occurs in the brain (Athauda and Foltynie, 2016a) with defective insulin signaling being identified as an important player in the pathogenesis of neurodegenerative disorders and particula…”
BackgroundBrain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 3×
“Binding of RAGEs by AGEs or other endogenous ligands induced by hyperglycemia is a known mechanism of systemic inflammation in DM and can trigger intracellular signaling cascades that lead to the activation of NF-κB (Bierhaus et al., 2005; Rong et al., 2005; Haslbeck et al., 2007).”
BackgroundDexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Nowotny, K., Jung, T., Höhn, A., Weber, D., & Grune, T. (2015) · Biomolecules · doi:10.3390/biom5010194 · Cited by 1,095 · cited 3×
“, 2002) and activating downstream mediators know to induce oxidative stress, such as the inducible nitric oxide synthase (iNOS; Nowotny et al., 2015).”
BackgroundDu, X. L., Edelstein, D., Dimmeler, S., Ju, Q., Sui, C., & Brownlee, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11235 · Cited by 907
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age
Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., Flint Beal, M., & Wallace, D. C. (1992) · Nature Genetics · doi:10.1038/ng1292-324 · Cited by 890
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 2×
“Disease-causing duplications (Chartier-Harlin et al., 2004) and triplications (Singleton et al., 2003) of the SNCA gene were identified, and other genes were added in subsequent years (Obeso et al., 2017).”
BackgroundPathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Supply and demand in cerebral energy metabolism: the role of nutrient transporters
Simpson, I. A., Carruthers, A., & Vannucci, S. J. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600521 · Cited by 812
Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
Ceriello, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1589 · Cited by 734
Intranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699
The role of mitochondria in the pathogenesis of type 2 diabetes
Patti, M.-E., & Corvera, S. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0027 · Cited by 551
Memory improvement following induced hyperinsulinemia in Alzheimer’s disease
Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., & Alderson, A. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02002-0 · Cited by 538
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · cited 2×
“…patients receiving dopamine-replacing therapy showed that twice-daily injections of exenatide for 12 months improved overnight off-medication motor symptoms and dementia, rated according to the unified PD rating scale and the Mattis dementia rating scale, respectively (Aviles-Olmos et al., 2013).”
BackgroundMethodBlood lactate is an important energy source for the human brain.
van Hall, G., Stømstad, M., Rasmussen, P., Jans, Ø., Zaar, M., Gam, C., Quistorff, B., Secher, N. H., & Nielsen, H. B. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.35 · Cited by 522 · cited 5×
“In the early stages of hyperglycemia, there is an upregulation of glucose flux through glycolysis and the tricarboxylic acid cycle (TCA).”
BackgroundInfluentialHyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
The facilitative glucose transporter GLUT3: 20 years of distinction
Simpson, I. A., Dwyer, D., Malide, D., Moley, K. H., Travis, A., & Vannucci, S. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90388.2008 · Cited by 473 · cited 5×
“…GLUT, is particularly abundant in the brain microvasculature, distributed with a 1:4 ratio between the luminal and abluminal surfaces of the endothelium, and plays a pivotal role in mediating glucose transport across the blood-brain barrier (Maher et al., 1994; Simpson et al., 2001, 2008).”
BackgroundInfluentialType 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Ageing and diabetes: implications for brain function
Biessels, G. J., van der Heide, L. P., Kamal, A., Bleys, R. L. A. W., & Gispen, W. H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01486-3 · Cited by 458
Hill, J. M., Lesniak, M. A., Pert, C. B., & Roth, J. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90082-5 · Cited by 413
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., Cuzzocrea, S., Zappia, M., Giordano, J., Calabrese, E. J., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.379 · Cited by 356
Sergi, D., Naumovski, N., Heilbronn, L. K., Abeywardena, M., O’Callaghan, N., Lionetti, L., & Luscombe-Marsh, N. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00532 · Cited by 347
Self-citationBlood—Brain Barrier Glucose Transporter: Effects of Hypo‐ and Hyperglycemia Revisited
Simpson, I. A., Appel, N. M., Hokari, M., Oki, J., Holman, G. D., Maher, F., Koehler‐Stec, E. M., Vannucci, S. J., & Smith, Q. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720238.x · Cited by 304
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302
Insulin in the Cerebrospinal Fluid
MARGOLIS, R. U., & ALTSZULER, N. (1967) · Nature · doi:10.1038/2151375a0 · Cited by 278 · cited 1×
“These preliminary findings led to the discovery that, besides being taken up through the bloodbrain barrier (Margolis and Altszuler, 1967; Woods and Porte, 1977; Banks et al., 1997a), insulin is synthesized by neurons within the mammalian brain (Dorn et al.”
BackgroundThe Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee, S. Y., & Kim, Y. S. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0105 · Cited by 274
Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228 · cited 1×
“In agreement with this, AKT phosphorylation has been reported to be decreased in the brain of PD patients following post mortem analysis (Malagelada et al., 2008).”
BackgroundUchiki, T., Weikel, K. A., Jiao, W., Shang, F., Caceres, A., Pawlak, D., Handa, J. T., Brownlee, M., Nagaraj, R., & Taylor, A. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2011.00752.x · Cited by 200
Anthony (2006) · doi:10.2337/db06-0376 · Cited by 195 · cited 2×
“Although insulin occupies an increasingly acknowledged role in the human CNS, by activating insulin-responsive neurons responsible for controlling appetite, peripheral glucose homeostasis, reward, cognition and memory (Craft et al., 1996; Benedict et al., 2004, 2007; Anthony et al., 2006; Hallschmid et al., 2008; Rege…”
BackgroundKuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168
Obese men respond to cognitive but not to catabolic brain insulin signaling
Hallschmid, M., Benedict, C., Schultes, B., Born, J., & Kern, W. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803722 · Cited by 165
Dietary sugars, not lipids, drive hypothalamic inflammation
Gao, Y., Bielohuby, M., Fleming, T., Grabner, G. F., Foppen, E., Bernhard, W., Guzmán-Ruiz, M., Layritz, C., Legutko, B., Zinser, E., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.008 · Cited by 131
Glucose Transporter Asymmetries in the Bovine Blood-Brain Barrier
Simpson, I. A., Vannucci, S. J., DeJoseph, M. R., & Hawkins, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010897200 · Cited by 99
Protein homeostasis and aging: Role of ubiquitin protein ligases
Jana, N. R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.02.009 · Cited by 67
Insulin Attenuates Diabetes-Related Mitochondrial Alterations: A Comparative Study
Moreira, P., Rolo, A., Sena, C., Seica, R., Oliveira, C., & Santos, M. (2006) · Medicinal Chemistry · doi:10.2174/157340606776930754 · Cited by 54
Cited by
The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction
Sergi, D., Boulestin, H., Campbell, F. M., & Williams, L. M. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900934 · Cited by 194
Self-citationBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
Russo, C., Valle, M. S., Russo, A., & Malaguarnera, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113432 · Cited by 40
Metadata
- Authors
- Sergi, D., Renaud, J., Simola, N., & Martinoli, M.-G.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-11-08
- Volume
- 11
- Pages
- 302-302
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2985453509
- Cited by
- 86
- References
- 53
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.